Achilles Therapeutics Valuation
| ACHL Stock | USD 1.12 0.01 0.88% |
Today, the firm appears to be overvalued. Achilles Therapeutics PLC shows a prevailing Real Value of $0.8 per share. The current price of the firm is $1.12. Our model approximates the value of Achilles Therapeutics PLC from analyzing the firm fundamentals such as return on equity of -0.44, and Current Valuation of (34.59 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Achilles Therapeutics' valuation include:
Overvalued
Today
Please note that Achilles Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Achilles Therapeutics PLC is based on 3 months time horizon. Increasing Achilles Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Achilles stock is determined by what a typical buyer is willing to pay for full or partial control of Achilles Therapeutics PLC. Since Achilles Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Achilles Stock. However, Achilles Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.12 | Real 0.8 | Target 0.5 | Hype 1.12 | Naive 1.05 |
The intrinsic value of Achilles Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Achilles Therapeutics' stock price.
Estimating the potential upside or downside of Achilles Therapeutics PLC helps investors to forecast how Achilles stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Achilles Therapeutics more accurately as focusing exclusively on Achilles Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Achilles Therapeutics' intrinsic value based on its ongoing forecasts of Achilles Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Achilles Therapeutics' closest peers.
Achilles Therapeutics Cash |
|
Achilles Valuation Trend
Knowing Achilles Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Achilles Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Achilles Therapeutics Total Value Analysis
Achilles Therapeutics PLC is presently forecasted to have valuation of (34.59 M) with market capitalization of 47.84 M, debt of 4.62 M, and cash on hands of 201.6 M. The negative valuation of Achilles Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Achilles Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(34.59 M) | 47.84 M | 4.62 M | 201.6 M |
Achilles Therapeutics Asset Utilization
One of the ways to look at asset utilization of Achilles is to check how much profit was generated for every dollar of assets it reports. Achilles Therapeutics PLC shows a negative utilization of assets of -0.27 percent, losing $0.002682 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Achilles Therapeutics PLC shows how unproductive it operates for each dollar spent on its assets.Achilles Therapeutics Ownership Allocation
Achilles Therapeutics holds a total of 41.1 Million outstanding shares. Over half of Achilles Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Achilles Therapeutics Profitability Analysis
Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0.About Achilles Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Achilles Therapeutics PLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Achilles Therapeutics PLC based exclusively on its fundamental and basic technical indicators. By analyzing Achilles Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Achilles Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Achilles Therapeutics. We calculate exposure to Achilles Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Achilles Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.3 M | -4 M |
Achilles Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Achilles Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40 M |
Achilles Therapeutics Current Valuation Indicators
Achilles Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Achilles Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Achilles Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Achilles Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Achilles Therapeutics' worth.When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.